
## Siobhan V Glavey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/649589/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Engineered nanomedicine for myeloma and bone microenvironment targeting. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10287-10292.	3.3	234
2	Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood, 2017, 129, 2429-2436.	0.6	214
3	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Reports, 2015, 12, 622-635.	2.9	123
4	Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood, 2014, 124, 3250-3259.	0.6	109
5	The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood, 2014, 124, 1765-1776.	0.6	97
6	The cancer glycome: Carbohydrates as mediators of metastasis. Blood Reviews, 2015, 29, 269-279.	2.8	91
7	Role of endothelial progenitor cells in cancer progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 26-39.	3.3	70
8	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular Cancer Therapeutics, 2018, 17, 1454-1463.	1.9	70
9	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Science Translational Medicine, 2017, 9, .	5.8	53
10	Pyk2 promotes tumor progression in multiple myeloma. Blood, 2014, 124, 2675-2686.	0.6	51
11	Clobal Epigenetic Regulation of MicroRNAs in Multiple Myeloma. PLoS ONE, 2014, 9, e110973.	1.1	29
12	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood, 2016, 127, 2598-2606.	0.6	22
13	Genomic Aberrations in Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 23-34.	0.2	21
14	Founding Precision Therapy in 1q-Amplified Multiple Myeloma. Blood, 2018, 132, 1007-1007.	0.6	12
15	Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma. Blood, 2014, 124, 3431-3431.	0.6	8
16	Epigenetics in Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 35-49.	0.2	7
17	American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma. Expert Review of Hematology, 2015, 8, 273-275.	1.0	5
18	Low Expression Of The FUCA1 Gene Is An Adverse Prognostic Factor In Myeloma and Combined With High Sialyltransferase Gene Expression Identifies Patients At Increased Risk Of Early Disease Progression and Death. Blood, 2013, 122, 1864-1864.	0.6	4

SIOBHAN V GLAVEY

#	Article	IF	CITATIONS
19	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. Blood, 2015, 126, 1770-1770.	0.6	4
20	Lin28B/Let-7 Axis Regulates Multiple Myeloma Proliferation By Enhancing c-Myc and Ras Survival Pathways. Blood, 2013, 122, 273-273.	0.6	3
21	Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients. Blood, 2013, 122, 3086-3086.	0.6	2
22	Nanoparticle Design For Bone-Specific Chemotherapy and Microenvironmental Targeting In Multiple Myeloma. Blood, 2013, 122, 881-881.	0.6	1
23	Clonal-Heterogeneity and Propensity for Bone Metastasis in Multiple Myeloma. Blood, 2014, 124, 3370-3370.	0.6	1
24	Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix. Blood, 2014, 124, 2051-2051.	0.6	1
25	Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo. Blood, 2013, 122, 275-275.	0.6	0
26	Methylation-Dependent Epigenetic Silencing Of Mir-152 and Mir-10b-5p Plays a Crucial Role In Modulating Tumor Progression In Multiple Myeloma. Blood, 2013, 122, 3751-3751.	0.6	0
27	Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells. Blood, 2014, 124, 3430-3430.	0.6	0
28	Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression. Blood, 2014, 124, 4719-4719.	0.6	0
29	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. Blood, 2014, 124, 2056-2056.	0.6	0
30	MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma. Blood, 2015, 126, 1755-1755.	0.6	0